Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $11.35 up 0.80% from its previous closing price of $11.26. In other words, the price has increased by $0.80 from its previous closing price. On the day, 1.01 million shares were traded. AUPH stock price reached its highest trading level at $11.3972 during the session, while it also had its lowest trading level at $11.1775.
Ratios:
For a deeper understanding of Aurinia Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.74 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.19. For the most recent quarter (mrq), Quick Ratio is recorded 4.63 and its Current Ratio is at 5.23. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.19.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 01 ’25 when TANG KEVIN bought 1,000,000 shares for $10.12 per share. The transaction valued at 10,120,000 led to the insider holds 11,029,500 shares of the business.
TANG KEVIN bought 200,000 shares of AUPH for $2,336,000 on Aug 05 ’25. The Director now owns 11,329,500 shares after completing the transaction at $11.68 per share. On Aug 04 ’25, another insider, TANG KEVIN, who serves as the Director of the company, bought 100,000 shares for $11.34 each. As a result, the insider paid 1,134,000 and bolstered with 11,129,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1493995392 and an Enterprise Value of 1260780288. As of this moment, Aurinia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 26.54, and their Forward P/E ratio for the next fiscal year is 14.90. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.74 while its Price-to-Book (P/B) ratio in mrq is 4.49. Its current Enterprise Value per Revenue stands at 4.847 whereas that against EBITDA is 15.267.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.30, which has changed by 0.6593567 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $13.54, while it has fallen to a 52-week low of $6.55. The 50-Day Moving Average of the stock is -3.64%, while the 200-Day Moving Average is calculated to be 24.93%.
Shares Statistics:
For the past three months, AUPH has traded an average of 2.14M shares per day and 2222780 over the past ten days. A total of 132.67M shares are outstanding, with a floating share count of 118.93M. Insiders hold about 9.76% of the company’s shares, while institutions hold 43.78% stake in the company. Shares short for AUPH as of 1757894400 were 8982210 with a Short Ratio of 4.19, compared to 1755216000 on 9064607. Therefore, it implies a Short% of Shares Outstanding of 8982210 and a Short% of Float of 7.48.
Earnings Estimates
The company has 6.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.15, with high estimates of $0.22 and low estimates of $0.07.
Analysts are recommending an EPS of between $0.81 and $0.5 for the fiscal current year, implying an average EPS of $0.65. EPS for the following year is $0.76, with 6.0 analysts recommending between $1.22 and $0.57.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $67.7M this quarter.It ranges from a high estimate of $71.1M to a low estimate of $65.03M. As of. The current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $67.77MFor the next quarter, 7 analysts are estimating revenue of $70.27M. There is a high estimate of $72.6M for the next quarter, whereas the lowest estimate is $66.5M.
A total of 7 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $276.2M, while the lowest revenue estimate was $265M, resulting in an average revenue estimate of $270.48M. In the same quarter a year ago, actual revenue was $235.13MBased on 7 analysts’ estimates, the company’s revenue will be $309.2M in the next fiscal year. The high estimate is $356.92M and the low estimate is $284.45M.
